Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.

Haematologica
Rachel E HaydenChris M Bunce

Abstract

Tumor cells in chronic lymphocytic leukemia accumulate in the periphery through the proliferation of a minority of cells in lymph nodes. The proliferative and survival signals in these proliferation centers include interactions with T lymphocytes expressing CD40 ligand. We have demonstrated that the low toxicity combination of bezafibrate and medroxyprogesterone acetate induces mitochondrial superoxide-mediated apoptosis of non-CD40-liganded cells but not of cells exposed to CD40 ligand. Here, we assessed the ability of dasatinib and lycorine to restore bezafibrate- and medroxyprogesterone acetate- induced apoptosis in cells exposed to CD40 ligand. In parallel experiments we compared the ability of dasatinib to induce apoptosis of cells co-treated with fludarabine. Primary chronic lymphocytic leukemia and peripheral blood mononuclear cells were exposed to drug combinations for 72 hours on control and CD40 ligand-expressing fibroblast monolayers. Cells were harvested and analyzed for apoptosis and levels of mitochondrial superoxide using flow cytometry. In some experiments cells were removed from CD40 ligand at 48 hours, retreated and analyzed after a further 24 hours. The effect of CD40 ligand and drug treatments on mitochondri...Continue Reading

References

Oct 19, 1995·The New England Journal of Medicine·C Rozman, E Montserrat
Apr 1, 1993·The Journal of Experimental Medicine·E A Ranheim, T J Kipps
Dec 12, 2003·Phytotherapy Research : PTR·Bilge SenerJutamad Satayavivad
Apr 17, 2004·British Journal of Haematology·D OscierUNKNOWN Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haematology
Dec 29, 2004·Leukemia & Lymphoma·Irene Munk Pedersen, John Reed
Feb 25, 2005·The New England Journal of Medicine·Nicholas ChiorazziManlio Ferrarini
Sep 16, 2005·Anti-cancer Drugs·Eliezer Flescher
Mar 31, 2006·Natural Product Reports·Peter J HoughtonMelanie-Jayne Howes
Apr 8, 2006·Cancer Letters·Eliezer Flescher
Jun 21, 2006·Chemical Biology & Drug Design·Zachary B MackeyJames H McKerrow
Nov 28, 2006·Cancer Letters·Alina Heyfets, Eliezer Flescher
Mar 6, 2007·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·J LiuW X Hu
Jun 5, 2007·Critical Reviews in Oncology/hematology·Paolo GhiaFederico Caligaris-Cappio
Oct 3, 2008·Cancer Letters·Xiao-shan LiuYing-mu Cai
Feb 7, 2009·Leukemia & Lymphoma·Barbara EichhorstMichael Hallek
Jul 14, 2009·Organic Letters·Matthew T JonesMartin G Banwell
Aug 1, 2009·Blood Reviews·Julio DelgadoJorge Sierra
Jan 29, 2010·Mini Reviews in Medicinal Chemistry·D Lamoral-TheysL Pottier

❮ Previous
Next ❯

Citations

Sep 9, 2011·The Journal of Organic Chemistry·Brett D SchwartzAnthony C Willis
Jan 1, 2013·Science China. Chemistry·ZhiFei CaoQuanSheng Zhou
Aug 17, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Mridul RoyJing Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis